Carysil net profit rises 23% to ₹32 crore in Q1FY26 on revenue growth
Carysil Limited delivered strong Q1FY26 results with consolidated net profit rising 23% to ₹32.05 crore and revenue growing 11% to ₹262.14 crore. Standalone profit also rose 23% to ₹18.85 crore. The Board approved enhanced credit facilities for its subsidiary and a leadership designation change.

*this image is generated using AI for illustrative purposes only.
Carysil Limited reported a consolidated net profit of ₹32.05 crore for the quarter ended June 30, 2026, marking a 23% year-on-year increase from ₹22.91 crore in Q1FY25. This growth was supported by an 11% rise in consolidated revenue from operations, which reached ₹262.14 crore compared to ₹226.99 crore in the corresponding period of the previous year. The results indicate sustained operational momentum, with basic earnings per share (EPS) climbing to ₹11.05 from ₹8.03 in Q1FY25.
The Board of Directors approved these unaudited standalone and consolidated financial results on August 10, 2026, following a review by the Audit Committee. Statutory auditors Park & Company issued an unmodified review report on the financial statements. In addition to approving the financials, the Board enhanced a corporate guarantee extended to HDFC Bank Ltd by ₹18 crore, bringing the aggregate guarantee to ₹55.10 crore. This facility secures enhanced credit lines for Carysilnox Limited, a subsidiary, to support ongoing capacity expansion initiatives.
Financial Performance
Standalone figures mirrored the consolidated growth trajectory. Standalone revenue from operations increased by 10% to ₹137.20 crore from ₹124.90 crore in Q1FY25. Standalone net profit rose 23% to ₹18.85 crore from ₹15.32 crore. Other income contributed significantly to the bottom line, standing at ₹5.00 crore compared to ₹2.66 crore in the previous year. Total comprehensive income for the consolidated group was ₹32.34 crore, up from ₹20.19 crore in Q1FY25.
| Metric | Standalone Q1FY26 | Standalone Q1FY25 | Consolidated Q1FY26 | Consolidated Q1FY25 |
|---|---|---|---|---|
| Revenue from Operations | ₹137.20 crore | ₹124.90 crore | ₹262.14 crore | ₹226.99 crore |
| Net Profit | ₹18.85 crore | ₹15.32 crore | ₹32.05 crore | ₹22.91 crore |
| Earnings Per Share (Basic) | ₹6.63 | ₹5.39 | ₹11.05 | ₹8.03 |
Corporate Actions and Governance
The Company scheduled its 39th Annual General Meeting for September 22, 2026, at 3:00 P.M. (IST) via Video Conferencing or Other Audio Visual Means. The trading window for designated persons reopened on August 13, 2026, following the conclusion of the Board meeting. Additionally, the Board approved changing the designation of Ms. Rhea Parekh from Vice President to Senior Vice President (International Marketing), effective October 1, 2026, subject to member approval at the ensuing Annual General Meeting. The corporate guarantee for Carysilnox Limited is disclosed as a contingent liability, with management stating no expected adverse financial impact based on current assessments.
Historical Stock Returns for CARYSIL
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.47% | +0.63% | +1.94% | +22.67% | +52.54% | +97.08% |
How will the capacity expansion initiatives at Carysilnox Limited impact future production volumes and market share in the specialty chemicals sector?
What is the expected timeline for the return on investment from the enhanced credit lines secured through the increased corporate guarantee to HDFC Bank?
Could the significant rise in other income be sustained in upcoming quarters, or was it driven by one-off events that may not recur?


































